<DOC>
	<DOCNO>NCT02993991</DOCNO>
	<brief_summary>This Phase 1 Window Opportunity study evaluate pharmacodynamic immune effect pre-operative therapy Mocetinostat Durvalumab patient squamous cell carcinoma oral cavity .</brief_summary>
	<brief_title>Pre-operative Mocetinostat ( MGCD0103 ) Durvalumab ( MEDI4736 ) ( PRIMED ) Squamous Cell Carcinoma Oral Cavity</brief_title>
	<detailed_description>This single center , open-label , non-randomized , pre-operative window opportunity study patient resectable squamous cell carcinoma oral cavity consider suitable curative-intent surgical resection , pre-operative Mocetinostat Durvalumab . This study involve treatment Mocetinostat Durvalumab , test procedure do safety collection blood sample biomarker research . Tissue sample ( fresh biopsy archival tissue ) also collect biomarker research evaluation .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>1 . Signed write voluntary informed consent . 2 . Patient must willing able comply schedule visit , treatment plan , laboratory test study procedure . 3 . Age &gt; 18 year , male female . Disease characteristics 4 . Patient must diagnose histologically confirm squamous cell carcinoma oral cavity ( SCCOC ) ( floor mouth , anterior 2/3 tongue , buccal mucosa , upper low gingiva , retromolar trigone ) consider resectable head neck surgical round ( T24a , N02 , M0 ; without evidence distant metastasis ) . 5 . Patient must willing able provide 2 fresh tumor biopsy histopathological biomarker evaluation ; first pretreatment baseline , second treatment mocetinostat prior treatment durvalumab . Patients decline inhouse fresh pretreatment tumor biopsy must give consent provide tumor block exist diagnostic primary tumor biopsy complete within 90 day enrollment , acceptable quality quantity analysis , assess study site correlative team . 6 . No antineoplastic treatment allow time obtain baseline tumor specimen enrollment . Patient characteristic 7 . ECOG performance status 01 . 8 . Patient must adequate organ function determine follow : Renal function : i. Serum creatinine &lt; 1.5 ULN ( upper limit normal range ) calculate creatinine clearance &gt; 50mL/min use follow formula : Creatinine clearance = [ ( 140age ) x wt ( kg ) x Constant* ] / creatinine ( umol/L ) *Constant = 1.23 men , 1.04 woman Bone marrow function ( without hematopoietic growth factor transfusion ) : . Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L ii . Leukocytes &gt; 3.0 x 109/L iii . Hemoglobin &gt; 90 g/L &gt; 9g/dL iv . Platelets &gt; 100 x 109/L Liver function : . Total bilirubin &lt; ULN ii . Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &lt; 2.5 x ULN Cardiac function : . A normal left ventricular ejection fraction ( LVEF ) &gt; 50 % absence clinically significant pericardial effusion , evidence echocardiogram perform within 4 week study commencement . 9 . Evidence postmenopausal status , negative urinary serum pregnancy test female premenopausal patient . Women consider postmenopausal amenorrheic 12 month without alternative medical cause . The follow agespecific requirement apply : Women &lt; 50 year age would consider postmenopausal amenorrheic 12 month follow cessation exogenous hormonal treatment luteinizing hormone folliclestimulating hormone level postmenopausal range institution underwent surgical sterilization ( bilateral oophorectomy , bilateral salpingectomy hysterectomy ) . Women ≥50 year age would consider postmenopausal amenorrheic 12 month follow cessation exogenous hormonal treatment , radiationinduced menopause last menses &gt; 1 year ago , chemotherapyinduced menopause last menses &gt; 1 year ago , underwent surgical sterilization ( bilateral oophorectomy , bilateral salpingectomy hysterectomy ) . 10 . Subject willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . 1 . Primary site head neck carcinoma unknown , lip , hard palate , skin , outside oral cavity . 2 . Patients tumor invade major vessel , show unequivocally image study . For patient tumor invade major blood vessel within 3mm carotid artery branch thereof , anticoagulant therapy ( include aspirin , nonsteroidal antiinflammatories , antiplatelet agent anticoagulant ) must discontinue . 3 . Patients prior history bleeding relate current head neck cancer . 4 . Patients history gross hemoptysis ( bright red blood ½ teaspoon per episode coughing ) &lt; 3 month prior enrollment . 5 . Prior concurrent radiation therapy tumor site plan resection . 6 . Any concurrent chemotherapy , biologic , immunologic hormonal therapy cancer treatment . Concurrent use hormone noncancerrelated condition ( eg , insulin diabetes hormone replacement therapy ) acceptable . 7 . Current prior use immunosuppressive medication within 14 day prior start dose . The following exception criterion : Intranasal , inhale , topical steroid , local steroid injection ( eg , intraarticular injection ) . Systemic corticosteroid physiologic dos exceed 10 mg/day prednisone equivalent . Steroids premedication hypersensitivity reaction ( eg , compute tomography scan premedication ) . 8 . Active documented history autoimmune disease within 2 year screen , include : Active prior document inflammatory bowel disease ( eg . Crohn 's disease , ulcerative colitis ) . Patients vitiligo , resolve childhood asthma/atopy , type I diabetes mellitus , Grave 's disease , Hashimoto 's disease , psoriasis require systemic treatment within past 2 year , exclude . 9 . History primary immune deficiency . 10 . History organ transplant require use immunosuppressive medication . 11 . Use live vaccine infectious disease within 4 week study treatment initiation . 12 . Known allergy reaction component Mocetinostat and/or Durvalumab formulation . 13 . Known history tuberculosis . 14 . Subjects know human immunodeficiency ( HIV ) positive . 15 . Subjects know hepatitis B C positive . 16 . Female patient pregnant breastfeeding . 17 . Male female patient reproductive potential willing use effective birth control screen 180 day follow last dose durvalumab . 18 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , unstable cardiac arrhythmia , active peptic ulcer disease gastritis , psychiatric illness/social situation would limit compliance study requirement , substantially increase risk incur adverse event Mocetinostat Durvalumab , compromise ability subject give write informed consent . 19 . Any condition , opinion Investigator , would interfere evaluation study regimen interpretation patient safety study result . 20 . Any previous treatment PD1 PDL1 inhibitor , include durvalumab . 21 . History another primary malignancy , except : Malignancy treat curative intent know active disease ≥5 year first dose study drug low potential risk recurrence , Adequately treat nonmelanoma skin cancer lentigo maligna without evidence disease , Adequately treat carcinoma situ without evidence disease . 22 . Major surgical procedure ( defined Investigator ) within 28 day prior first dose study medication . 23 . Any prior Grade ≥3 immunerelated adverse event ( irAE ) receive previous immunotherapy agent , unresolved irAE &gt; Grade 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>